

Development and evaluation of a novel high-capacity protein A chromatography resin with significantly increased alkaline stability

> Jelena Vasić, Annika Forss, Tomas Björkman, and Mats Ander GE Healthcare Bio-Sciences AB, Björkgatan 30, 75184 Uppsala, Sweden


### Abstract

This poster presents the development and evaluation of a novel protein A chromatography resin. The significantly increased capacity and alkaline stability of the resin is enabled by base matrix optimization and protein engineering. Resin performance data, that is, yield and purity, in a mAb purification step is also presented.

### Background

Sensitive amino acids and/or exposed protein surfaces were mutated to increase alkaline stability (Fig 1). More than 400 constructs were screened using the Biacore<sup>™</sup> surface plasmon resonance (SPR) system. The MabSelect SuRe<sup>™</sup> ligand was used as reference. The most alkaline-stable constructs were selected and coupled to a base matrix for further

evaluation in packed columns. A new base matrix was also developed and optimized towards the new ligand (Fig 2). To increase binding capacity, base matrix properties such as particle size, matrix volume, and pore size were optimized in combination with ligand length and density (Fig 3).



# Results

#### **Dynamic binding capacities**

Dynamic binding capacities (DBC) were determined by frontal analysis. All resins were packed in 2 mL columns. Polyclonal IgG was applied on the columns at different flow rates, yielding residence times (RT) of

#### **Alkaline stability**

Repetitive purification cycles were performed with buffers only using 0.5 or 1.0 M NaOH as cleaning agent for 15 min/cycle. The capacity was evaluated every 25<sup>th</sup> cycle with polyclonal IgG. The results show that the newly developed MabSelect PrismA resin has significantly higher alkaline stability than its predecessors MabSelect SuRe LX and MabSelect SuRe resins (Fig 5). MabSelect PrismA has:

#### mAb purification


Purification performance of MabSelect PrismA was compared with MabSelect SuRe and MabSelect SuRe LX using the same mAb. The sample load was 80% of Q<sub>B10</sub> (63 mg/mL for MabSelect PrismA; 43 mg/mL for MabSelect SuRe LX; and 36 mg/mL for MabSelect SuRe). The chromatogram for MabSelect PrismA is shown in Figure 6. The results summarized in Table 1 show that yield and purity were comparable for the different protein A resins.

#### 1, 2.4, 4, 6, and 10 min.

Compared with MabSelect SuRe LX, the results displayed in Figure 4 show that MabSelect<sup>™</sup> PrismA offers:

- Up to 40% increased DBC at 2.4 min RT.

- Less than 10% loss of capacity after 300 cycles with 0.5 M NaOH.



### Conclusions

- New optimized ligand with better alkaline stability.
- New base matrix with optimized particle size, pore size, and porosity.

- Performance in terms of recovery and purity is similar to reference protein A resins.
- The improved alkaline stability enables efficient cleaning of the resin using 0.5 to 1.0 M NaOH.
- The new base matrix combined with a longer ligand increases the dynamic binding capacity at all studied residence times.

• The use of 1.0 M NaOH for sanitization will improve bioburden control.

## gelifesciences.com/bioprocess

GE, the GE Monogram, Biacore, MabSelect SuRe, MabSelect, and Tricorn are trademarks of General Electric Company. © 2018 General Electric Company All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information. GE Healthcare Bio-Sciences AB, Björkgatan 30, 751 84 Uppsala, Sweden GE Healthcare UK Ltd., Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK GE Healthcare Europe GmbH, Munzinger Strasse 5, D-79111 Freiburg, Germany GE Healthcare Bio-Sciences Corp., 100 Results Way, Marlborough, MA 01752, USA HyClone Laboratories Inc., 925 W 1800 S, Logan, UT 84321, USA GE Healthcare Japan Corp., Sanken Bldg., 3-25-1, Hyakunincho Shinjuku-ku, Tokyo 169-0073, Japan For local office contact information, visit gelifesciences.com/contact KA2429010318PO